Physician profile
Christopher Lee
NPI 1629257035
$48,125.47
in general payments reported to CMS, 2019-2025
32 companies · $6,319 in 2025
The $6,319 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $4,497 · 2021: $11K · 2022: $9,537 · 2023: $1,725 · 2024: $1,611 · 2025: $6,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,200 · Food and Beverage: $4,442 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,200.00 |
| Food and Beverage | $4,441.60 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $43,573.96 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $877.94 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $807.54 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Pfizer INC. | $471.79 | 2019-2025 | |
| Genzyme Corporation | $462.55 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $296.81 | 2022-2025 | Dupixent |
| Celgene Corporation | $221.60 | 2021-2024 | Zeposia |
| Vivus LLC | $199.43 | 2019-2025 | Qsymia, Pancreaze |
| Nestle Healthcare Nutrition INC. | $125.00 | 2022 | |
| Intercept Pharmaceuticals, INC. | $123.96 | 2021-2024 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.03 | 2019-2025 | Xifaxan |
| Lilly USA, LLC | $92.49 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $91.96 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $87.97 | 2025 | Rezdiffra |
| Micro-Tech Endoscopy USA, INC. | $62.50 | 2023 | Eyemax |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $59.53 | 2019-2021 | |
| Gilead Sciences, INC. | $59.05 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $54.54 | 2019-2020 | |
| Redhill Biopharma INC. | $51.02 | 2020-2023 | Talicia |
| Braintree Laboratories, INC. | $34.61 | 2023-2024 | Suflave |
| Endo Pharmaceuticals INC. | $32.08 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.21 | 2023 | Cyltezo |
| Amgen INC. | $27.38 | 2022 | |
| Covidien Lp | $25.00 | 2019 | |
| Biocon Biologics INC | $25.00 | 2024 | Hulio |
| Ferring Pharmaceuticals INC. | $24.50 | 2020 | |
| Ardelyx, INC. | $23.74 | 2023 | Ibsrela |
| Celltrion USA INC. | $20.29 | 2024 | Vegzelma |
| Endogastric Solutions, INC | $19.80 | 2024 | Esophyx |
| Shionogi INC | $17.33 | 2019 | |
| Allergan, INC. | $16.64 | 2019 | |
| Daiichi Sankyo INC. | $14.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.